Compare QNCX & INFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QNCX | INFU |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0M | 182.4M |
| IPO Year | 2019 | 2005 |
| Metric | QNCX | INFU |
|---|---|---|
| Price | $0.10 | $9.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $10.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 33.4M | 114.4K |
| Earning Date | 01-01-0001 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 181.82 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $143,436,000.00 |
| Revenue This Year | N/A | $2.89 |
| Revenue Next Year | N/A | $7.66 |
| P/E Ratio | ★ N/A | $30.29 |
| Revenue Growth | N/A | ★ 6.36 |
| 52 Week Low | $0.09 | $4.61 |
| 52 Week High | $4.55 | $11.04 |
| Indicator | QNCX | INFU |
|---|---|---|
| Relative Strength Index (RSI) | 27.86 | 57.19 |
| Support Level | $0.09 | $8.57 |
| Resistance Level | $0.98 | $9.80 |
| Average True Range (ATR) | 0.01 | 0.51 |
| MACD | 0.09 | 0.06 |
| Stochastic Oscillator | 18.57 | 77.48 |
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.